Circulating microRNA‑103a‑3p could be a diagnostic and prognostic biomarker for breast cancer
- Hui Liu
- Qing-Zhao Bian
- Wei Zhang
- Hai-Bin Cui
Affiliations: Department of Thyroid and Breast Surgery, Cangzhou Central Hospital, Cangzhou, Hebei 061000, P.R. China
- Published online on: December 3, 2021 https://doi.org/10.3892/ol.2021.13156
Copyright: © Liu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Breast cancer (BC) is the most frequent cancer for women worldwide. Recently, a spectrum of cell‑free circulating microRNAs (miR) has been recognized as promising biomarkers for BC diagnosis and prognosis, among which miR‑103a‑3p has been reported in several types of human cancer. However, the role of miR‑103a‑3p in BC remains unknown. A total of 112 patients with BC and 59 healthy controls were recruited into the present study. The expression level of serum miR‑103a‑3p was evaluated using reverse transcription‑quantitative PCR. Receiver operating characteristic curves were utilized to calculate diagnostic accuracy. Survival curves were generated to analyze survival outcomes. It was found that circulating miR‑103a‑3p level was upregulated in patients with BC compared with that in healthy controls, and its expression was decreased following surgery. In addition, miR‑103a‑3p expression level was also associated with advanced clinicopathological features, including positive epidermal growth factor receptor 2 status, metastasis and an advanced TNM stage. The circulating serum miR‑103a‑3p level could be used to discriminate between patients with BC and the healthy controls prior to surgery using an area under curve [(AUC), 0.697; 95% confidence intervals (CI), 0.615‑0.778], and distinguish patients with BC and metastasis from those without metastasis (AUC, 0.936; 95% CI, 0.892‑0.980). In addition, high expression level of miR‑103a‑3p was associated with worse survival outcomes in patients with BC. In conclusion, the present study suggests that miR‑103a‑3p could be a potential non‑invasive diagnostic and prognostic biomarker for BC.